Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences (VTYX)
NASDAQ:VTYX
VTYX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.78 - $3.40
Previous CloseN/A
Volume4.54M
Average Volume (3M)1.62M
Market Cap
$188.58M
Enterprise ValueN/A
Total Cash (Recent Filing)$217.32M
Total Debt (Recent Filing)$10.79M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Aug 07, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding71,161,200
10 Day Avg. Volume2,041,642
30 Day Avg. Volume1,622,513
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$17.50Price Target Upside560.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Ventyx Biosciences News
PremiumCompany Announcements
Ventyx Biosciences Holds Annual Stockholders Meeting
PremiumCompany Announcements
Ventyx Biosciences Reports Q1 2025 Financial Results
Bulls Say, Bears Say
Bulls Say
Financial StabilityVentyx Biosciences has sufficient financial resources, with $252.9 million in cash and marketable securities expected to fund operations into at least the second half of 2026.
Research And DevelopmentSanofi's investment and exclusive negotiation rights indicate strong interest and confidence in Ventyx's research and development capabilities.
Strategic InvestmentSanofi made a $27M strategic investment in Ventyx in exchange for an exclusive right of first negotiation for certain program rights related to Ventyx's CNS-penetrant NLRP3 inhibitor, VTX3232.
Bears Say
Market SkepticismShort interest is relatively high at 11.5% of the float, indicating some market skepticism or bearish sentiment towards the stock.
Obesity Treatment CompetitionThere is skepticism about competing in the obesity space with a monotherapy, as it is a highly competitive development path.
Study LimitationsThe small size of the Parkinson's study may limit insights until a larger Phase 2 study is conducted.
Ownership Overview
24.83% Insiders
9.68% Mutual Funds
23.71% Other Institutional Investors
33.43% Public Companies and Individual Investors
VTYX FAQ
What was Ventyx Biosciences’s price range in the past 12 months?
Ventyx Biosciences lowest stock price was $0.78 and its highest was $3.40 in the past 12 months.
What is Ventyx Biosciences’s market cap?
Ventyx Biosciences’s market cap is $188.58M.
When is Ventyx Biosciences’s upcoming earnings report date?
Ventyx Biosciences’s upcoming earnings report date is Aug 07, 2025 which is in 56 days.
How were Ventyx Biosciences’s earnings last quarter?
Ventyx Biosciences released its earnings results on May 08, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.484 by $0.094.
Is Ventyx Biosciences overvalued?
According to Wall Street analysts Ventyx Biosciences’s price is currently Undervalued.
Does Ventyx Biosciences pay dividends?
Ventyx Biosciences does not currently pay dividends.
What is Ventyx Biosciences’s EPS estimate?
Ventyx Biosciences’s EPS estimate is -0.46.
How many shares outstanding does Ventyx Biosciences have?
Ventyx Biosciences has 71,161,200 shares outstanding.
What happened to Ventyx Biosciences’s price movement after its last earnings report?
Ventyx Biosciences reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.484. Following the earnings report the stock price went up 5.983%.
Which hedge fund is a major shareholder of Ventyx Biosciences?
Currently, no hedge funds are holding shares in VTYX
Ventyx Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (560.38% Upside)
$17.50 (560.38% Upside)
Blogger Sentiment
Bearish
VTYX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 440.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.96%
12-Months-Change
Fundamentals
Return on Equity
-46.04%
Trailing 12-Months
Asset Growth
-23.67%
Trailing 12-Months
Company Description
Ventyx Biosciences
Ventyx Biosciences (VTYX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel, small molecule drugs for the treatment of inflammatory and autoimmune diseases. The company is engaged in the research and development of therapies targeting clinically validated mechanisms, with an emphasis on addressing significant unmet medical needs. Ventyx's core product candidates are designed to modulate key pathways involved in immune system regulation, providing potential new treatments for conditions such as psoriasis, Crohn's disease, and ulcerative colitis.
VTYX Stock 12 Month Forecast
Average Price Target
$17.50
▲(560.38%Upside)
Technical Analysis
Assembly Biosciences
―
Acumen Pharmaceuticals
―
TScan Therapeutics
―
Context Therapeutics
―
Rani Therapeutics Holdings
―